A study in colorectal cancer cells and patient organoids identified the RNA-binding protein IGF2BP2 as a controller of tumor cell metabolism through regulation of mitochondrial transporters and lipid composition. By integrating mechanistic experiments with organoid validation, the researchers placed IGF2BP2 at the intersection of central carbon metabolism and lipid handling—two pathways that frequently support rapid growth and therapy resistance. The results also suggest IGF2BP2-dependent metabolic wiring may produce tractable biomarkers or vulnerabilities. For translational teams, the report strengthens the metabolic targeting rationale in colorectal cancer beyond broad pathway inhibition, by pointing to specific regulators of mitochondrial-lipid coupling.